<DOC>
	<DOCNO>NCT00504907</DOCNO>
	<brief_summary>This placebo-controlled , double-blind , randomise , single dose escalation Phase I clinical trial determine safety tolerability BTA9881 administer orally healthy subject</brief_summary>
	<brief_title>Safety Study Oral BTA9881 Treat RSV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1 . Healthy male female subject &gt; =18 &lt; =45 year age . 2 . Individuals freely give Informed Consent write . 3 . Male subject use appropriate contraception ( e.g . condom ) time interval dose three month dose . Female subject must surgically sterile postmenopausal ( define least two year post cessation menses and/or folliclestimulating hormone ( FSH ) &gt; 18 mIU/mL serum oestradiol &lt; 110 pmol/L ) , must agree use two form follow contraception : oral contraceptive , form hormonal birth control include hormonal vaginal ring transdermal patch , intrauterine device , condom , spermicide time interval dose three month dose . Female subject must also nonlactating negative serum pregnancy test screen baseline . 4 . Able perform nasal wash procedure . 5 . Normotensive ( systolic BP ≤ 140 mm Hg diastolic BP ≤ 90 mm Hg ) . 6 . No abnormal find clinical relevance screen examination Investigator considers might interfere objective clinical trial . 7 . No clinically relevant abnormality ECG ; QTc &lt; 430 m ( male ) &lt; 450 m ( female ) . 8 . Healthy base medical history , physical examination , 12lead ECG clinical laboratory test , disease Investigator regard clinically relevant . 9 . Negative result Human Immunodeficiency Virus ( HIV ) antibody , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody test . 10 . Willingness abstain alcohol caffeinecontaining food beverage 48 hour prior dose duration clinical trial . 1 . Use prescription medication ( allowable oral contraceptive implant hormonal contraceptive ) 14 day prior dose . 2 . Use nonprescription ( 'over counter ' ) product , include herbal product , diet aid , hormone supplement , etc. , within 14 day prior dose . 3 . Intake investigational drug within 3 month prior dose . 4 . History clinical evidence significant cardiovascular disease ( include risk factor cardiac arrhythmia ) previous history cardiovascular condition , opinion investigator , would interfere conduct trial . 5 . History clinical evidence significant cerebrovascular , cardiovascular , gastrointestinal , haematological disease , myocardial infarction , previous history serious underlying disease ( include immunocompromised subject and/or neutropenic subject ) , opinion investigator would interfere conduct clinical trial . 6 . History clinical evidence significant respiratory disease ( include asthma , chronic obstructive pulmonary disease , cystic fibrosis and/or recurrent low respiratory tract infection ) , upper respiratory tract infection within last month lower respiratory tract infection within last three month . 7 . History clinical evidence renal disease ( include renovascular occlusive disease ) , nephrectomy and/or renal transplant , and/or previous clinically significant laboratory abnormality renal function parameter . All subject serum creatinine proteinuria outside normal laboratory reference range screen baseline regard Investigator clinically significant . 8 . History clinical evidence hepatic disease and/or previous clinically significant laboratory abnormality liver function parameter . All subject bilirubin , gamma glutamyl transferase ( GGT ) , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) outside normal laboratory reference range screen baseline , regard Investigator clinically significant . Subjects know experienced elevate liver enzyme value previous clinical study also exclude . 9 . History clinical evidence adrenal disease ( include Cushing 's Syndrome Addison 's disease ) thyroid disease ( include hyper hypothyroidism ) , and/or previous clinically significant laboratory abnormality adrenal thyroid function parameter . All subject thyroid function ( TSH , FT4 , FT3 ) outside normal laboratory reference range baseline regard Investigator clinically significant . 10 . Psychiatric emotional problem would invalidate give Informed Consent limit ability subject comply clinical trial requirement . 11 . Body Mass Index ( BMI ) ≤18.5 kg/m2 &gt; =30.0 kg/m2 . 12 . History alcohol and/or drug abuse within 1 year prior screening ( verified drug screening ) . 13 . Receipt blood blood product , loss 450 mL blood , last three month prior dose . 14 . Unwillingness inability provide Informed Consent participate satisfactorily entire clinical trial period . 15 . Subjects smoke nonsmoker less 3 month prior dose . 16 . Subjects previously enrol clinical trial . 17 . Poor vein , fear venipuncture sight blood , know allergy hypersensitivity lidocaine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>RSV</keyword>
</DOC>